Regional Variations in the Pharmacology of NMDA Receptor Channel Blockers: Implications for Therapeutic Potential
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Quantitative receptor autoradiography was used to examine the regional binding characteristics of a diverse group of N‐methyl‐d‐aspartate (NMDA)‐receptor channel blockers that varied in potency 10 5‐fold. Full competition curves were generated in each of six brain regions for 11 different compounds. MK‐801 was the most potent compound studied, with an IC 50 of ∼10 n M in the forebrain regions and 24 n M in the cerebellar granule cell layer (p < 0.05). The binding affinities of nine of the 11 compounds examined were significantly different in cerebellar granule cell layer than in forebrain regions. In addition, the apparent Hill slopes of five of the compounds were significantly different in cerebellum compared with forebrain. That the rank order of drug potencies in cerebellum diverges from that in forebrain suggests that cerebellar NMDA‐receptor ion channels differ pharmacologically from those in forebrain. There was a general trend that drugs known to be well tolerated in humans (remacemide hydrochloride and its metabolites, amantadine, budipine, and memantine) had lower affinities than compounds with severe neurobehavioral or psychotomimetic effects. Moreover, all of the compounds known to be well tolerated in humans had a significantly higher affinity in the cerebellum than in forebrain regions, in contrast to MK‐801, 1‐[1‐(2‐thienyl)cyclohexyl]‐piperidine hydrochloride (TCP), phencyclidine (PCP), and ketamine, which had lower affinities in cerebellum. Our results are consistent with the notion that low affinity (rapid kinetics) and, possibly, subunit specificity (as indicated by distinct regional pharmacologies) may be important determinants of the clinical tolerability of NMDA‐receptor channel blockers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A family of metabotropic glutamate receptors
Tanabe, Y., Masu, M., Ishii, T., Shigemoto, R., & Nakanishi, S. (1992) · Neuron · doi:10.1016/0896-6273(92)90118-w · Cited by 940
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Parsons, C. G., Danysz, W., & Quack, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00019-2 · Cited by 878
Parsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 707
The Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives
Wanka, L., Iqbal, K., & Schreiner, P. R. (2013) · Chemical Reviews · doi:10.1021/cr100264t · Cited by 696
Survival after Treatment of Rabies with Induction of Coma
Willoughby, R. E., Tieves, K. S., Hoffman, G. M., Ghanayem, N. S., Amlie-Lefond, C. M., Schwabe, M. J., Chusid, M. J., & Rupprecht, C. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050382 · Cited by 661
Metadata
- Authors
- Porter, R. H. P., & Greenamyre, J. T.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 1995-02
- Volume
- 64
- Issue
- 2
- Pages
- 614-623
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2036492577
- Cited by
- 136
- References
- 1
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Regional Variations in the Pharmacology of NMDA Receptor Channel Blockers: Implications for Therapeutic Potential. https://app.cochat.ai/papers/10.1046/j.1471-4159.1995.64020614.x
- The paper
- Porter, R. H. P., & Greenamyre, J. T. (1995). Regional Variations in the Pharmacology of NMDA Receptor Channel Blockers: Implications for Therapeutic Potential. Journal of Neurochemistry. https://doi.org/10.1046/j.1471-4159.1995.64020614.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.